tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SNY Stock Latest News

Trump administration mulls charging patent holders 1%-5% fee, WSJ reports
The FlyTrump administration mulls charging patent holders 1%-5% fee, WSJ reports
9h ago
AZN
BMY
Sanofi’s SAR443579 Study: A Potential Game-Changer in Hematological Malignancies
PremiumCompany Announcements
Sanofi’s SAR443579 Study: A Potential Game-Changer in Hematological Malignancies
13h ago
SNY
Regeneron and Sanofi’s EoE Study: A Potential Market Game-Changer
PremiumCompany Announcements
Regeneron and Sanofi’s EoE Study: A Potential Market Game-Changer
4d ago
SNY
REGN
Sanofi’s Frexalimab Study: A Potential Game-Changer in Multiple Sclerosis Treatment
PremiumCompany Announcements
Sanofi’s Frexalimab Study: A Potential Game-Changer in Multiple Sclerosis Treatment
4d ago
SNY
Sanofi’s Promising Phase 2 Study on AATD Emphysema Treatment: Key Insights for Investors
PremiumCompany Announcements
Sanofi’s Promising Phase 2 Study on AATD Emphysema Treatment: Key Insights for Investors
4d ago
SNY
Sanofi’s Promising Phase 2a Study: A Potential Game-Changer in Nephrology
PremiumCompany AnnouncementsSanofi’s Promising Phase 2a Study: A Potential Game-Changer in Nephrology
4d ago
SNY
Sanofi’s Phase 3 Study on Belumosudil for Chronic GVHD: A Market Game-Changer?
Premium
Company Announcements
Sanofi’s Phase 3 Study on Belumosudil for Chronic GVHD: A Market Game-Changer?
4d ago
SNY
Sanofi’s Strategic Acquisition of Vicebio Enhances Vaccine Portfolio and Supports Buy Rating
Premium
Ratings
Sanofi’s Strategic Acquisition of Vicebio Enhances Vaccine Portfolio and Supports Buy Rating
5d ago
SNY
Regeneron and Sanofi’s EoE Study with DUPIXENT®: Key Insights for Investors
PremiumCompany Announcements
Regeneron and Sanofi’s EoE Study with DUPIXENT®: Key Insights for Investors
6d ago
SNY
REGN
Sanofi’s Phase 3 Study on Frexalimab: A Potential Game-Changer for Multiple Sclerosis Treatment
PremiumCompany Announcements
Sanofi’s Phase 3 Study on Frexalimab: A Potential Game-Changer for Multiple Sclerosis Treatment
6d ago
SNY
Sanofi says Beyfortus RSV study in babies met endpoints
PremiumThe Fly
Sanofi says Beyfortus RSV study in babies met endpoints
7d ago
SNY
Sanofi’s SAR446597 Gains Fast Track Status and Vicebio Acquisition Announced
PremiumCompany Announcements
Sanofi’s SAR446597 Gains Fast Track Status and Vicebio Acquisition Announced
7d ago
6K
SNY
Sanofi’s Chlamydia Vaccine Study: A Promising Step Forward
PremiumCompany AnnouncementsSanofi’s Chlamydia Vaccine Study: A Promising Step Forward
8d ago
SNY
Sanofi’s Innovative Approach in Type 1 Diabetes Treatment: A Clinical Study Update
Premium
Company Announcements
Sanofi’s Innovative Approach in Type 1 Diabetes Treatment: A Clinical Study Update
11d ago
SNY
Sanofi’s New Study on Lunsekimig for Chronic Rhinosinusitis: A Potential Game Changer?
Premium
Company Announcements
Sanofi’s New Study on Lunsekimig for Chronic Rhinosinusitis: A Potential Game Changer?
11d ago
SNY
Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough in Eosinophilic Gastritis Treatment
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough in Eosinophilic Gastritis Treatment
11d ago
SNY
REGN
Sanofi’s Phase 3 Study on Amlitelimab for Atopic Dermatitis: A Potential Game-Changer?
PremiumCompany Announcements
Sanofi’s Phase 3 Study on Amlitelimab for Atopic Dermatitis: A Potential Game-Changer?
11d ago
SNY
Regeneron and Sanofi’s AROMA Study: Long-Term Insights on DUPIXENT® for CRSwNP
PremiumCompany Announcements
Regeneron and Sanofi’s AROMA Study: Long-Term Insights on DUPIXENT® for CRSwNP
11d ago
SNY
REGN
Sanofi Finalizes Acquisition of Blueprint Medicines
PremiumCompany Announcements
Sanofi Finalizes Acquisition of Blueprint Medicines
11d ago
6K
SNY
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis
PremiumCompany AnnouncementsRegeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis
12d ago
SNY
REGN
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game Changer for Chronic Rhinosinusitis
Premium
Company Announcements
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game Changer for Chronic Rhinosinusitis
12d ago
SNY
REGN
Sanofi’s Promising Ulcerative Colitis Study: A Potential Game-Changer?
Premium
Company Announcements
Sanofi’s Promising Ulcerative Colitis Study: A Potential Game-Changer?
12d ago
SNY

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >